CAMBRIDGE, Mass. ( TheStreet) -- First quarter sales of Ironwood Pharmaceuticals' (IRWD) irritable bowel drug Linzess missed Wall Street expectations by a wide margin but marketing partner Forest Labs (FRX) forecast improved sales for the remainder of the year.
Ironwood shares are down 10% to $16.05 in Tuesday pre-market trading.
Net sales of Linzess totaled $4.5 million for the quarter ended March 30, well below analyst expectations of sales in the $11-13 million range. Linzess was approved in December, so the first quarter represented the first three months of the drug's commercial launch. The drug is sold in the U.S. by Forest Labs under a partner with Ironwood.
Neither company provided an explanation for Linzess' disappointing first-quarter sales, but J.P. Morgan analyst Geoff Meacham, in an email to clients, blamed inventory write-downs from the fourth quarter of last year.Forest Labs said it expects Linzess sales of $170 million for its 2014 fiscal year which ends March 31, 2014. J.P. Morgan's Meacham says the Linzess guidance is higher than the current consensus of approximately $155 million. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV